Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23773855 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL6514198 | 0.89 | TDP1 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL86328 | 0.89 | TDP1 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL21083738 | 0.86 | HDAC6 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL26346003 | 0.86 | HDAC6 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL18556956 | 0.86 | HDAC6 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL24881082 | 0.85 | CA1 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL86238 | 0.85 | AAK1 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL25536966 | 0.85 | AAK1 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 | |
| SCHEMBL5565289 | 0.85 | AAK1 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745365-B2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3312292-B1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORP (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-1885875-B1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORP (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190031629-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2019-01-31 | — | — | US | disclosed |
| EP-2778234-B1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORP (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160176830-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176830-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-06-23 | — | — | US | disclosed |
| EP-2277872-B1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORP (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2015-11-05 | — | — | US | disclosed |
| US-9107915-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2006053082-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| CN-1680326-A | Pharmaceutical compositions and methods for use | TARGACEPT INC (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1311265-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6743812-B1 | 2,3-DIACYLTARTARIC ACID SALTS OF E-METANICOTINE; NERVOUS SYSTEM DISORDERS; AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES | TARGACEPT, INC. | 2004-06-01 | — | — | US | disclosed |
| CN-1468100-A | pharmaceutical compositions and methods of use | ���Ͽع�����˾ | 2004-01-14 | — | — | CN | disclosed |
| CN-1452486-A | pharmaceutical compositions and methods of use | TARGACEPT INC (US) | 2003-10-29 | — | — | CN | disclosed |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | DULL GARY MAURICE (US) | 2003-05-08 | — | — | US | disclosed |
| US-6492399-B1 | SUCH AS N-METHYL-4-(3-(5-NITRO-6-AMINOPYRIDIN)YL)-3-BUTEN-1-AMINE; NICOTINIC CHOLINERGIC RECEPTOR AGONISTS | TARGACEPT, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6432954-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 573/4885CHRNA4 1876/4885CHRNB4 713/4885 |
| US-10745365-B2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | CHRNB2 3985/4885CHRNA4 4606/4885CHRNB4 4031/4885 |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, HTR3E | CHRNB2 227/4885CHRNA4 145/4885CHRNB4 168/4885 |
| US-20190031629-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | GLB1, NOD1, PYCARD | CHRNB2 3985/4885CHRNA4 4606/4885CHRNB4 4031/4885 |
| US-20160176830-A1 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | GLB1, NOD1, PYCARD | CHRNB2 3925/4885CHRNA4 4575/4885CHRNB4 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.